USC neuroscientist faces scrutiny following allegations of data manipulation

The campus of the Keck School of Medicine of USC. “Consistent with federal regulations and USC policies, the university forwards any such allegations to its Office of Research Integrity for careful review,” the university said in a statement. “And so I think that motivates people to just go along.” In its report, the journal Science interviewed four former employees of Zlokovic’s lab who said that Zlokovic routinely pressured them to manipulate data. “Appropriate steps would be for USC to ask Zlokovic to give them the lab’s notebooks and data,” Bik said. Last year, Kent Pryor, ZZ Biotech’s chief executive, called the drug “a potential game-changer.” “I believe, based on the positive clinical results to date, our 3K3A-APC will potentially create the first new drug class to treat ischemic stroke since 2003,” Pryor said.